U.S. markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,857.30
    +3.40 (+0.18%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.01%)
     
  • BTC-USD

    29,001.53
    +342.37 (+1.19%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • ChromaDex Corp (NASDAQ: CDXC) has launched its flagship consumer product Tru Niagen in Walmart Inc (NYSE: WMT), available in 3,800 stores across the U.S.

  • The NAD+ booster will be offered to Walmart customers in two distinct serving sizes, 100mg and 300mg.

  • Tru Niagen is a form of vitamin B3 clinically proven to elevate NAD+, reducing the impact of aging and daily wear and tear on the body.

  • NAD+ is a vital coenzyme naturally produced in the body, and studies have shown NAD+ declines up to 50% between the ages of 40 and 60.

  • Based on a 300mg/day serving, Tru Niagen can increase NAD+ by 40-50%.

  • Related content: ChromaDex CEO Rings Nasdaq Closing Bell, Talks Walmart Product Launch.

  • Price Action: CDXC shares are up 11.7% at $9.99 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.